GPR88 impairs the signaling of kappa opioid receptors in a heterologous system and in primary striatal neurons

Fecha de publicación

2025-12-10T16:33:16Z

2025-12-10T16:33:16Z

2025-03-01

2025-12-10T16:33:17Z



Resumen

The physiological role of GPR88, an orphan G protein-coupled receptor (GPCR) predominantly expressed in the striatum, remains unclear, despite its altered expression in parkinsonian animal models. GPR88 is known to interact with other GPCRs. Specifically, GPR88 expression inhibits signaling mediated by the μ-opioid receptor in cells coexpressing both receptors. The effect of GPR88 on the kappa-opioid receptor (KOR) is less understood. In this study, we examine the interaction between GPR88 and KOR, and the impact of GPR88 expression on KOR-mediated signaling in heterologous cells and primary striatal neurons. Bioluminescence resonance energy transfer and proximity ligation assays revealed an interaction between GPR88 and KOR. Functional assays showed that GPR88 antagonized the effects of U69,593, a selective KOR agonist, on forskolin-stimulated cAMP levels, β-arrestin-2 recruitment, and phosphorylation of extracellular signal-regulated kinases (ERK1/2) in HEK-293T cells coexpressing both receptors. In primary striatal neurons, GPR88 and KOR complexes were observed, with KOR activation effects enhanced when GPR88 expression was suppressed using RNA interference. These results suggest that GPR88 and KOR are coexpressed in striatal neurons, where GPR88 inhibits KOR activation. Notably, the GPR88-KOR heteromer was more prevalent in dopamine D1-receptor-containing neurons of the direct pathway of the basal ganglia. Given the roles of KORs in dopamine release, motor function regulation, and pain and reward perception, the GPR88-KOR interaction warrants further investigation in the context of neuropathic pain, Parkinson's disease, and neuropsychiatric disorders.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

Elsevier Ltd.

Documentos relacionados

Reproducció del document publicat a: https://doi.org/10.1016/j.neuropharm.2024.110242

Neuropharmacology, 2025, vol. 265

https://doi.org/10.1016/j.neuropharm.2024.110242

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

cc-by-nc (c) Rivas‐Santisteban, Rafael et al., 2025

http://creativecommons.org/licenses/by-nc/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)